Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on April 1, 2026 to 20 new non-executive employees under its 2025 Inducement Plan.
The independent Compensation Committee approved a total of 8,079 time-based restricted stock units that vest in four equal annual installments, subject to continued employment.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – MDGL
+1.54%
+1.54%Session close to close
In the Apr 8 session, MDGL gained 1.54%, reflecting a mild positive market reaction.
This announcement details routine equity inducement awards: 8,079 time-based RSUs granted to 20 new ...
Analysis
This announcement details routine equity inducement awards: 8,079 time-based RSUs granted to 20 new non-executive employees, vesting over four years and subject to continued employment. It follows several similar inducement updates under the 2025 Inducement Plan. In context of strong 2025 net sales of $958.4M and a solid cash balance, investors may monitor how ongoing hiring and stock-based compensation align with long-term commercial and R&D execution.
Key Figures
Current share price:$533.88Inducement RSUs:8,079 RSUsNew employees:20 employees+5 more
8 metrics
Current share price$533.88Pre-news trading level on publication date
Inducement RSUs8,079 RSUsTime-based restricted stock units granted April 1, 2026
New employees20 employeesNon-executive hires receiving inducement equity awards
Vesting schedule4 equal installmentsAnnual vesting over four years from grant date
Shares outstanding22,939,969 sharesAs of 03/06/2026 per Form 144 filing
Net sales 2025$958.4MFull-year 2025 net sales from Feb 19, 2026 earnings
Cash & securities$988.6MCash and marketable securities at Dec. 31, 2025
Short interest18.57%Reported short percent of float in risk context
RSU grants for five new employees with four-year time-based vesting.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent inducement award announcements typically coincided with modest, mixed price reactions, with a slight bias toward small declines.
Recent Company History
Over recent months, Madrigal has repeatedly announced equity inducement awards under its 2025 Inducement Plan (e.g., grants on Feb 15, Mar 1, and Mar 15, 2026), each tied to time-based vesting over four years. These routine HR updates produced mild price moves, including -2.88%, -1.48%, and +0.86% reactions. Alongside this, the company reported substantial 2025 net sales of $958.4M and a strong cash position of $988.6M, while also engaging in conference participation and ongoing insider equity activity.
"The new employees received, in the aggregate, 8,079 time-based restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq listing rule 5635(c)(4)regulatory
"approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
equity inducement awardsfinancial
"it granted equity awards on April 1, 2026 to 20 new non-executive employees as equity inducement awards"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
inducement planfinancial
"employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan."
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
CONSHOHOCKEN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on April 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 8,079 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact Tina Ventura, IR@madrigalpharma.com
Media Contact Christopher Frates, media@madrigalpharma.com
FAQ
What did Madrigal (MDGL) announce on April 7, 2026 about inducement awards?
Madrigal announced grants of inducement restricted stock units to new hires on April 1, 2026. According to the company, 20 non-executive employees received an aggregate of 8,079 time-based RSUs under the 2025 Inducement Plan, approved by the independent Compensation Committee.
How do the MDGL inducement restricted stock units vest and when do vesting dates occur?
The RSUs vest in four equal annual installments beginning one year after grant. According to the company, each installment vests on the first through fourth anniversaries of the April 1, 2026 grant date, subject to each employee's continued employment on the vesting date.
Why did Madrigal (MDGL) grant inducement awards under Nasdaq Listing Rule 5635(c)(4)?
The awards were granted as inducements to hire new employees consistent with Nasdaq rule requirements. According to the company, the independent Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4) and the company’s 2025 Inducement Plan.
How many restricted stock units did Madrigal (MDGL) grant and to whom were they awarded?
Madrigal granted an aggregate of 8,079 time-based restricted stock units to 20 new non-executive employees. According to the company, the awards were inducement grants tied to acceptance of employment and subject to standard vesting conditions.
Will the MDGL inducement RSUs affect shareholder dilution materially?
The announcement specifies an aggregate grant of 8,079 RSUs but does not quantify dilution percentage. According to the company, the awards are time-based inducement grants; investors must compare the aggregate RSUs to total shares outstanding to assess dilution impact.
